
News|Articles|June 1, 2004
New molecular entity: Apomorphine injection
First therapy approved for “off” episodes in advanced Parkinson’s disease
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
2
The MASLD-breast cancer connection
3
Transforming care through social determinants of health
4
FDA approves Lumvoa, first TED therapy labeled for both active and chronic disease
5






























